Discussion
Animal, but not human, studies have found lithium to be associated with increased neural tube defects manifesting as exencephaly (2) . Anencephaly has been seen in only one animal study (3) , whereas evidence for association with exencephaly is more robust (2) . However, sonographic and pathologic evidence points to a close link between exencephaly and anencephaly, with exencephaly being seen as a stage in the development of anencephaly (4).
Our patient became pregnant while taking lithium, and the fetus developed anencephaly. The possible association of anencephaly with lithium in this patient cannot be ruled out, owing to the temporal relation of lithium use in the first 6 to 8 weeks of pregnancy (the period of embryogenesis and most vulnerable period for developing CMF), the absence of a family history of CMF, and exencephaly-anencephaly being recognized as occuring in animal studies involving lithium.
Sandeep Grover, MD Chandigarh, India Nitin Gupta, MD, Burton upon Trent, UK
Aripiprazole-Induced Seizure
Dear Editor: Antipsychotics, both typical and atypical, have been known to lower seizure threshold. Aripiprazole is a novel atypical antipsychotic that is a partial agonist at dopamine D 2 and serotonin 1A (5-HT 1A ) receptors and has antagonist activity at the 5-HT 2 receptor. The risk of seizures with aripirazole is reported to be 0.1% (1), the lowest among atypical agents. Our literature search revealed no report of seizure induction with aripiprazole.
Case Report
Mr A, aged 31 years, was brought to the emergency department after a motor vehicle accident. He had lost control of his vehicle, which landed in a ditch. He carried a diagnosis of delusional disorder and major depression; aripiprazole 15 mg daily had recently been added to sertraline 150 mg daily that he had been taking for the past 2 years. Both the patient and his family suspected that a seizure had caused the accident, since they were perplexed by the circumstances of the crash. The patient denied that he had attempted suicide. Mr A was restarted on aripiprazole while he was in the intensive care unit. About 3 weeks later, he had a witnessed partial complex seizure on the ward. There was no evidence of any medical cause for the seizure. His laboratory tests were within normal limits, except for a serum magnesium level of 1.7 mg/dL (the lower normal being 1.8 mg/dL). He was started on levetiracetam, and his aripiprazole was later discontinued, because it was considered to be the offending agent. The patient was subsequently transferred to the rehabilitation unit, where he stayed seizure-free. He was discharged home after an adequate recovery.
Discussion
Seizure induction from antipsychotic drugs is not a new phenomenon. Several risk factors are known, including a personal or family history of epilepsy, head trauma, and concomitant use of another drug known to lower seizure threshold (2) . Since experience with aripiprazole is limited at this time, the risk of lowering of seizure threshold with this drug may actually be higher than reported in the premarketing studies. Our patient possibly had 2 separate seizures, one of which was the witnessed event that occured when the medication was reinitiated, making the likelihood high that aripiprazole was the offender.
Medical causes were ruled out, and there were no other implicated medications.
For optimum outcomes, high vigilence is needed to promptly identify the cause of seizures in patients taking psychotropic medications. The relevence of seizure secondary to aripiprazole needs further elucidation.
Prevalence of Bipolar Disorder and Major Depression Among Patients Seen in Primary and Secondary Care in Finland
Dear Editor: The underdiagnosis of bipolar disorder (BD) and its frequent misdiagnosis as major depressive disorder (MDD) appear to be major problems in patients with BD. Few studies focus on the prevalence of BD and MDD among primary care and psychiatric service patients. In Finland, more than 66% of the population visit a community health care centre during a year; 5% of the population are treated in primary care for a mental disorder, and 3% receive psychiatric treatment (1).
The Finnish Tampere Depression Project (TADEP) was a study that used the Present State Examination (9th version) to assess the prevalence of BD and MDD in primary and secondary care. The Index of Definition cutoff point of > 4 was used to identify cases of BD (ICD-8 diagnosis 296.1). A DSM-III-R assessment was also carried out. The study setting, patients, and data collection methods are reported in detail elsewhere (2, 3) .
Results
A total of 437 patients in primary care and 435 patients in secondary care were interviewed. In community health centres, the 1-month and 12-month prevalences of BD were 0.9% and 2.1%, respectively. In community mental health centres, the corresponding figures were 4.4% and 7.6%. In The Canadian Journal of Psychiatry
